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Abstract Myelin transcription factor 2 (MYT2), a putative
transcription factor found in the human central nervous system,
was cloned from an expression cDNA library from human
T-cells. MYT2 shares weak similarity to bacterial type I
topoisomerases and shares 63% sequence identity to a replicase
from Leuconostoc mesenteroides. MYT2 preferentially binds
supercoiled DNA (scDNA). Incubation of MYT2 and scDNA at
or above equal molar ratios generated topoisomer-like patterns
that were abolished by deproteination. Thus, MYT2 appears to
relax scDNA via a non-enzymatic mechanism. The banding
pattern of MYT2^scDNA complexes was shown to be quanti-
sized, saturable and sequence-independent. Microinjection of
MYT2 mRNA induced Go growth-arrested NIH 3T3 cells to
enter the S phase of the cell cycle.
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1. Introduction
DNA topology plays an important role in many key cellular
processes such as DNA replication, recombination, repair,
and transcription [1^3]. Proteins that bind and induce topo-
logical changes in DNA have profound e¡ects on gene tran-
scription [4]. For example, structural factors YY1 [5] and
HMG1 [6] function as transcription factors by a¡ecting
DNA structure rather than by directly contacting the tran-
scription machinery. The topology of DNA can be altered
either enzymatically by topoisomerases or non-enzymatically
by DNA-binding proteins, such as Escherichia coli single-
stranded DNA-binding protein [7], prokaryotic DNA ligase
[8], HIV-1 nucleocapsid protein [9], HMG [10], and p53 [11].
We recently cloned from a human T-cell cDNA expression
library a novel DNA-binding protein that is almost identical
to the newly described myelin transcription factor 2 (MYT2)
[12]. MYT2 is a DNA-binding protein that is expressed in the
central nervous system and was suggested to belong to a class
of proteins involved in cellular growth control and survival in
the nervous system. Intriguingly, MYT2 is secreted even
though it binds to DNA, and it is a putative transcription
factor function [12]. Here we present evidence that MYT2
preferentially binds and relaxes supercoiled DNA (scDNA),
and is able to stimulate DNA synthesis in quiescent mamma-
lian cells. This protein is homologous to the bacterial topo-
isomerase I family, and is 63% identical to a replicase from
Leuconostoc mesenteroides. Interestingly, no identi¢able ho-
mologs exist in the completed genomes of yeast and Caeno-
rhabditis elegans.
2. Materials and methods
2.1. Cloning
A 5P-stretch human Hut-78 T-cell Vgt-11 cDNA expression library
was purchased from Clontech. This library was screened using a 43 bp
oligonucleotide probe derived from the 381 to 339 region of the
HIV-1 LTR and contained three methylated Sp1 transcription factor
binding sites. The sequence of the probe was 5PAGGGAG-
GMGTGGCCTGGGMGGGACTGGGGAGTGGMGAGCCCTC3P
where M represents 5-methylcytosine. The probe was labeled with
[Q-32P]ATP at the 5P end of the plus strand and annealed with 50%
excess of unlabeled minus strand as previously described [13] and the
labeled probe was further catenated [14]. The Hut-78 cDNA expres-
sion library was screened with this probe according to the procedure
described by Singh and coworkers [15]. Puri¢ed positive phage
plaques were used to infect E. coli Y1090r3 according to the manu-
facturer’s instructions. The supernatant containing the phage isolate
was stored in 50% sterile glycerol at 380‡C.
The insert was ampli¢ed from the phage isolate using nested PCR
with the following primers: 5P-GACTCCTGGAGCCCG-3P (5P outer
primer), 5P-GGTAGCGACCGGCGC-3P (3P outer primer), 5P-GG-
AATTCATATGGATAGTTCATTAAGTATTATAACATACTC-3P
(5P inner primer with NdeI restriction site), and 5P-CCGCTCGAGAC-
TATTAGTATTAGTTCTGTGCGTTAAAC-3P (3P inner primer with
XhoI restriction site). PCR reactions were performed in 50 Wl volumes
containing 0.5 WM primers, 0.2 mM of each dNTP, 10 Wl of 10x Pfu
PCR reaction bu¡er and 2.5 units Pfu polymerase (Stratagene). PCR
reactions were conducted as follows: 1 cycle of 94‡C for 5 min, fol-
lowed by 30 cycles of 94‡C for 45 s, 51‡C for 45 s, 72‡C for 3 min,
and ¢nally 1 cycle of 72‡C for 5 min. After gel puri¢cation, the PCR
fragment was cloned into pCR-blunt (Invitrogen) and was digested
with NdeI and XhoI. The insert was subcloned into pET24 (Novagen)
with 6UHis-tag at the 3P end of the gene. This construct was named
pMYT2.
2.2. Expression and puri¢cation
MYT2 was expressed in E. coli Bl21 (DE3). The cells were induced
by 1 mM IPTG at OD600 = 0.8 and grown for 8 h at 20‡C after
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induction. Cell disruption was performed by subsequent brief sonica-
tion in ice cold Dulbecco’s PBS containing 0.5 M NaCl, 1 WM leu-
peptin, and 0.5 mM PMSF. Cell debris were removed by centrifuga-
tion (19 000 rpm, 20 min, Sorvall-34) at 4‡C; the supernatant was
applied to a POROS MC 20 resin Ni-IMAC column (4.6U100 mm)
using a BioCAD 700E system (PerSeptives Biosystems). The protein
was eluted with a linear gradient from 0 to 500 mM imidazole. The
protein-containing fractions were combined and dialyzed against Bu¡-
er A (50 mM Tris^HCl, pH 7.5, 10% glycerol) at 4‡C and were
applied to a phosphocellulose column (20 ml Whatman P11) equili-
brated in the same bu¡er, containing 1 mM EDTA. MYT2 was eluted
with a linear gradient of 0^1 M NaCl. Fractions containing protein
were combined, dialyzed overnight at 4‡C against 1 l of dialysis bu¡er
containing 30 mM HEPES, pH 7.5, 0.25 mM EDTA, and 10% glyc-
erol, and stored at 380‡C. The purity of MYT2 was examined with
Novex 10^20% Tris^Glycin gel according to the manufacturer’s in-
struction.
2.3. Gel shift assay
The plus strand of the 43 bp cDNA screening oligonucleotide was
biotinylated at the 3P end. It was either used as a single-strand probe
or annealed with an equal amount of the minus strand to form a
double-stranded probe. The methylated probe was designated as A
and the non-methylated probe as B. The reaction was conducted as
described [13], except for using a 50 fold more excess of poly(dIdC) as
non-speci¢c competitor. The reaction was incubated on ice for 20 min,
loaded on a pre-run 6% DNA Retardation Gel (Novex), and run at
85 V in a Novex Xcell II electrophoresis apparatus for about 1 h. The
gel was transferred to a Pall Biodyne A membrane (Gibco BRL Life
Technologies) in a Bio-Rad Trans-Blot SD Semi-Dry Transfer Cell at
50 mA for 30 min. The Southern-light Chemiluminescent Detection
system (Tropix) was used to detect the free probe and binding com-
plex according to the manufacturer’s instructions.
2.4. Electron microscopy
Carbon-coated support-¢lmed grids were glow-discharged for 2 min
and attached at the edges to a double-sided adhesive tape. The DNA-
protein mixture (5 Wl) was placed on the grids allowing the complex to
adsorb for 2 min, then the grids were washed three times with glass-
distilled water for 1 min each. The grids were dehydrated in 80%
alcohol solution, stained with 80% alcohol containing 0.002% uranyl
acetate, and washed in an 80% alcohol solution. The grids were air-
dried on ¢lter paper and rotary shadowed with platinum^palladium at
an angle of 6‡ in a Denton vacuum evaporator. The grids were exam-
ined and photographed with a Hitachi H-7000 electron microscope
operated at 50 kV.
2.5. Topoisomerase I activity assay
A topoisomerase I assay kit from TopoGen was used to test the
possible topoisomerase activity of MYT2. Typically, the assay was
done in 20 Wl using the supplied assay bu¡er according to the man-
ufacturer’s instructions. The concentrations of MYT2 and DNA are
indicated in the text. The reaction was carried out at 37‡C for half an
hour and terminated by adding stop and loading bu¡er. The mixture
was then loaded on a 1% agarose gel and electrophoresed until the
dye front reached the bottom of the gel. The gel was stained with 0.5
Wg/ml ethidium bromide. As a positive control, human topoisomerase
I (Gibco Life Technologies) was assayed under the same conditions as
MYT2.
2.6. Sequence analysis
Wisconsin Sequence Analysis Package (GCG) and MacVector 6.0
(Oxford Molecular Group) was used for sequence analysis.
2.7. Microinjection
Plasmid pMYT2 was linearized with XhoI and used as the template
for in vitro transcription of the MYT2 gene with In Vitro Transcrip-
tion kit MEGAscript (Ambion). The MYT2 mRNA was microin-
jected into approximately 50 quiescent NIH 3T3 cells and the subse-
quent incorporation of tritiated thymidine into their nuclei was
detected according to the method previously described [16].
Fig. 1. SDS^PAGE analysis of puri¢ed MYT2 protein. Lane 1, mo-
lecular weight markers; lane 2, 1 Wg of total protein; lane 3, 2.5 Wg
of total protein; lane 4, 5 Wg of total protein.
Fig. 2. The comparison of MYT2 binding to the methylated and
non-methylated 43 bp oligonucleotide probes derived from the Sp1
binding site region of HIV-1 LTR. Lanes 1^4, methylated oligonu-
cleotide; lanes 5^8, non-methylated oligonucleotides; lanes 1 and 5,
25 ng of oligonucleotides; lanes 2 and 6, 50 ng of oligonucleotides;
lanes 3 and 7, 100 ng of oligonucleotides; lanes 4 and 8, 200 ng oli-
gonucleotides. Protein MYT2 in lanes 1^8: 370 ng; lane 9, 200 ng
non-methylated oligonucleotide, without protein MYT2. C: Repre-
sents MYT2:DNA probe complex.
Fig. 3. The amino acid sequence of MYT2 and the sequence align-
ment of MYT2 and RepC. A: Amino acid sequence of MYT2. B:
Sequence alignment of p44 and RepC. Highly conserved fragments
are underlined. # represents the tyrosine residue essential for the
topoisomerase I activity of RepC [21]. RepC contains 314 amino
acids.
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3. Results
3.1. Isolation and initial characterization of MYT2
We previously identi¢ed a HIV-1 methylated DNA-binding
protein (HMBP) present in a human T-cell line, that prefer-
entially binds to methylated Sp1 binding sites in the HIV-1
LTR [13]. In an attempt to isolate HMBP, a human Hut-78
cDNA expression library was screened with a methylated and
catenated oligonucleotide probe derived from the 381 to 339
region of the HIV-1 LTR. One of the phage clones that
yielded a positive probe-binding signal contained an insert
of 1343 bp which encodes a polypeptide of 375 amino acid
residues with a calculated molecular weight of 44.2 kDa
(MYT2). BLAST analysis of the GenBank database revealed
that MYT2 was almost identical to the newly described
MYT2 [12] except that there is a valine substituted for a
leucine at position 158 in MYT2. MYT2 was subcloned
with a His6-tag at its C-terminus, expressed in E. coli
BL21(DE3), and puri¢ed to homogeneity using metal chelate
and phosphocellulose chromatography (Fig. 1).
We then characterized MYT2 binding to oligonucleotides
derived from the Sp1 binding region of HIV-1 LTR (Fig. 2).
In contrast to what we expected to ¢nd for HMBP, our data
showed that MYT2 bound equally well to methylated (Fig. 2,
lanes 1^4) and non-methylated oligonucleotide (Fig. 2, lanes
5^8) under the assay conditions. One explanation for this
result is that MYT2 may be one component of HMBP and
may not preferentially bind methylated DNA in the absence
of other components. Alternatively, MYT2 may be unrelated
to HMBP.
Sequence analysis indicates that MYT2 represents a novel
human protein composed of a basic N-terminal region (resi-
dues 1^199 have a pI of 9.2) followed by an acidic C-terminal
region (residues 200^375 have a pI of 4.8). In fact, a 43 res-
idue segment (329^365) contains 11 glutamic or aspartic acid
residues (Fig. 3A). Anionic regions with a high percentage of
glutamic and aspartic acid residues have been implicated in
protein^protein interactions [17], and also are characteristic of
many proteins that interact with chromatin, such as, centro-
mere protein CENP-B, chromatin assembly proteins N1/N2,
topoisomerase I, and HMG [18]. The N-terminal region is
typical of nucleic acid binding proteins which are rich in basic
residues.
3.2. MYT2 generates a topoisomer-like pattern in scDNA
MYT2 shares sequence similarity with a family of plasmid-
encoded trans-acting replication initiator (Rep) proteins from
Staphylococcus aureus, all of which have type-I topoisomerase
Fig. 4. MYT2 generates topoisomer-like pattern on scDNA. A: Topoisomer-like patterns of MYT2:scDNA complexes. The e¡ect varying
MYT2 concentrations on ladder pattern formation using 14 nM of pHOT1: lane 1, no protein; lane 2, 14 nM protein (protein:DNA ratio:
1:1); lane 3, 35 nM protein (2.5:1); lane 4, 70 nM protein (5:1); lane 5, 140 nM protein (10:1); lane 6, 280 nM protein (20:1); lane 7, 560
nM (40:1); lane 8, 2240 nM protein (160:1); lane 9, 3500 nM protein (350:1); lane 10, partially relaxed pHOT1 by human topoisomerase I.
SC: scDNA. B: The e¡ect of varying scDNA concentration on ladder pattern formation using 400 nM of MYT2: lane 1, 10 nM supercoiled
pHOT1 without protein; lane 2, 10 nM supercoiled pHOT1 (protein:DNA ratio: 40:1); lane 3, 15 nM supercoiled pHOT1 (25:1); lane 4, 20
nM supercoiled pHOT1 (20:1). SC: scDNA. C: Ladder patterns using other plasmids at 10 nM. lanes 1, 3, and 5, no protein; lanes 2, 4, and
6, 200 nM protein; lanes 1 and 2: pHOT1; lanes 3 and 4; pUC18; lanes 5 and 6; pBluescript II SK(-). SC: scDNA.
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activity [19]. Fig. 3B shows the alignment of MYT2 and RepC
encoded by pT181 [20]. Although the overall sequence identity
is only 23%, the alignment of MYT2 and RepC reveals several
highly conserved segments, including FNPNH(K)L and IR-
L(I)YD(N)K (Fig. 3B). The conserved tyrosine residue at po-
sition 191 in the second segment is the active site tyrosine of
the RepC topoisomerase I [21].
To test for potential topoisomerase activity, MYT2 was
incubated with supercoiled pHOT1 DNA at 37‡C and ana-
lyzed on an agarose gel (Fig. 4A). Interestingly, this reaction
yielded a pattern similar to the partial relaxation pattern gen-
erated by human topoisomerase I (Fig. 4A, lane 10). The
number of the topoisomer-like bands increased as the molar
ratio of MYT2 to scDNA increased from 1:1 to 160:1. How-
ever, the bands became less distinct as more protein was
added, and at a ratio of MYT2:scDNA of 350:1, only a
wide, di¡use band was observed (Fig. 4A, lane 9).
Similar results were observed when the DNA concentration
was varied at a ¢xed protein concentration (Fig. 4B). At a
MYT2:scDNA molar ratio of 40:1, several distinct bands
were observed (Fig. 4B, lane 2). Reducing the MYT2:scDNA
ratio by increasing the DNA concentration caused an increase
in the intensity of the bands, but did not increase the number
of bands observed (Fig. 4B, lanes 3 and 4). These results
suggest that there is a ¢xed number of binding sites on the
scDNA.
To test the sequence speci¢city of scDNA binding, MYT2
was incubated with two other plasmids, pUC18 and pBlue-
script II SK (-) (Fig. 4C). Similar banding patterns were
formed with both plasmids, implying that scDNA relaxation
by MYT2 is not sequence-dependent. Based on the concen-
tration dependence of the banding patterns (Fig. 4A,B), we
estimate the a⁄nity between MYT2 and scDNA to be below
35 nM.
3.3. MYT2 binds to scDNA in a manner similar to tumor
suppressor p53
The binding of MYT2 to scDNA (pHOT1) was visualized
using electron microscopy. Fig. 5A shows that one or more
MYT2 molecules bind to the pHOT1 plasmid when they are
mixed at a stoichiometry of 42:1 (12 nM pHOT1 and 0.5 WM
MYT2). However, after the same amount of pHOT1 was in-
cubated with 2 WM MYT2, each pHOT1 plasmid had many
bound MYT2 molecules, and some plasmids appeared to be
covered with bound MYT2 (Fig. 5B). Interestingly, the
pHOT1 plasmids displayed a relaxed conformation after
MYT2 binding. A similar result was observed by electron
microscopy with the tumor suppressor p53 which also induces
relaxation of scDNA [11].
The MYT2 scDNA complexes were treated with proteinase
K to better resolve the banding pattern. Surprisingly, the to-
poisomer-like patterns disappeared completely, and the DNA
was restored to its original supercoiled conformation (Fig. 6).
In contrast, proteinase K treatment did not a¡ect the DNA
Fig. 5. Electron microscopic image of MYT2^DNA complexes
formed from the incubation of 12 nM pHOT1 and (A) 0.5 WM
MYT2; and (B) 2 WM MYT2. Arrows point to MYT2 bound to
DNA.
Fig. 6. E¡ects of proteinase K digestion on ladder patterns of
MYT2:scDNA complexes. Proteinase K of a ¢nal concentration of
50 Wg/ml was added to MYT2:scDNA complexes prepared using
14 nM pHOT1 DNA and MYT2 at the indicated concentrations.
Digestion was performed at 37‡C for 30 min. Lane 1, 280 nM
MYT2; lane 2, 560 nM MYT2; lane 3, 3500 nM, MYT2. SC:
scDNA.
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topoisomers generated with human topoisomerase I (data not
shown). Since the DNA linking number is evidently unaltered
by the presence of MYT2, these results suggest that MYT2
does not possess topoisomerase I enzymatic activity under the
assay conditions used here. Instead, MYT2 seems to behave
more like tumor suppressor p53 in the sense that its e¡ect on
DNA conformation is reversed by proteolysis.
3.4. Topoisomer-like pattern formed only on scDNA
Since MYT2 must be present to maintain the topoisomer-
like banding pattern, and since the number of bands depends
on the protein:DNA ratio, it is possible that the pattern is
generated by di¡erent numbers of MYT2 molecules binding
to the DNA in a more or less quantized fashion. To test this
possibility, MYT2 was added to partially relaxed sc and linear
DNA forms generated using human topoisomerase I and
EcoRI cleavage, respectively. In contrast to the case with
scDNA, no topoisomer-like bands were generated with linear
DNA at molar ratios from 1:1 to 160:1 (protein:DNA) (Fig.
7A, lanes 2^5), although band shifts were evident at the higher
protein:DNA ratios (lanes 6^8). Similarly, MYT2 had only a
slight e¡ect on the banding pattern of partially relaxed DNA
(Fig. 7B). Taken together, these results indicate that MYT2
preferentially binds to scDNA.
3.5. MYT2 induces DNA synthesis in resting cells
During the course of this study, we discovered that the se-
quence MYT2 is highly similar to a 337 residue replicase
encoded by the plasmid pFR18 from L. mesenteroides [22].
The two proteins exhibit 63% amino acid sequence identity
over their entire length with two long identical segments; the
largest one is 20 residues in length and includes the topoiso-
merase I-like segment, IRLYDK (Fig. 8). The pFR18 repli-
case has been implicated in DNA synthesis in L. mesenteroides
[22] and may provide clues about the function of MYT2 in
mammalian cells. To test whether MYT2 plays a role in DNA
replication, MYT2 mRNA was prepared and injected into
quiescent NIH 3T3 cells grown in medium containing reduced
serum to decrease the cell division rate. Tritiated thymidine
was added to the medium 24 h after injection, and the cells
were subsequently ¢xed and autoradiographed. Injection of 25
Wg/ml MYT2 mRNA into NIH 3T3 cells led to an increased
incorporation of [3H]thymidine in 60% of cell nuclei (Fig. 9A).
In contrast, no thymidine incorporation could be seen in cells
after injection of 25 Wg/ml mRNA of L-galactosidase (Fig.
9B). These results demonstrated that the injection of MYT2
mRNA induces quiescent NIH 3T3 cells to enter the S phase
of the cell cycle and to synthesize DNA.
4. Discussion
MYT2 represents a novel human DNA-binding protein.
The existence of a highly acidic C-terminal segment suggests
that MYT2 might be involved in protein^protein interactions,
Fig. 7. E¡ect of MYT2 banding patterns of linear or partially relaxed DNA. A: Binding of MYT2 to linear pHOT1. Linear pHOT1 used in
all lanes was 14 nM. Lane 1, without protein; lane 2, 14 nM protein (protein:DNA ratio: 1:1); lane 3, 35 nM protein (2.5:1); lane 4, 70 nM
protein (5:1); lane 5, 140 nM protein (10:1); lane 6, 280 nM protein (20:1); lane 7, 560 nM (40:1); lane 8, 2240 nM protein (160:1). B: Bind-
ing of p44 to partially relaxed pHOT1. Partially relaxed pHOT1 used in all lanes was 14 nM. lane 1, without protein; lane 2, 14 nM protein
(protein:DNA ratio: 1:1); lane 3, 35 nM protein (2.5:1); lane 4, 70 nM protein (5:1); lane 5, 140 nM protein (10:1); lane 6, 280 nM protein
(20:1); lane 7, 560 nM (40:1); lane 8, 2240 nM protein (160:1).
Fig. 8. The comparison between MYT2 and pFR18 rep protein.
The underlined fragment is the one corresponding to the topoiso-
merase I active site area of RepC. pFR18 rep protein contains 337
amino acids.
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and possibly in chromosomal function [17,18]. However, we
can not exclude the possibility that MYT2 has a speci¢c bind-
ing target on chromosomal DNA yet to be found. Speci¢c
DNA-binding proteins often bind to non-speci¢c DNA se-
quences with lower a⁄nity as a mechanism to locate the spe-
ci¢c sites as well as to regulate gene expression [23]. MYT2 is
expressed in the cells of human central nervous system and
reportedly binds to the proteolipid protein promoter [12].
We found that MYT2 binds preferentially to scDNA and
generates a topoisomer-like pattern. However, that pattern is
not the result of typical topoisomerase activity since it only
occurs with stoichiometric amounts of protein and is abol-
ished by proteolytic digestion of MYT2. One explanation
for the banding pattern is that each band represents a fully
scDNA molecule complexed with di¡erent numbers of MYT2
molecules. The separation of the bands would then be based
on molecular weight di¡erences of the di¡erent complexes. No
e¡ects on the banding pattern were seen with either partially
relaxed circular or linear DNA, with MYT2:DNA ratios up
to 10:1, indicating that these patterns were not simply gener-
ated by molecular weight shifts. However, gel shifts for MYT2
complexed under similar conditions with a small double-
stranded oligonucleotide probe could readily be observed
(data not shown). These results suggest that the lack of the
observed gel shifts with the linear 1755 kDa DNA plasmid is
due to an inability to detect small incremental molecular
weight changes induced by binding with limited numbers of
the MYT2 proteins. Another explanation for the ladder-like
pattern is that there may be a limited number of MYT2 bind-
ing sites in the scDNA that are critical for maintaining a
certain writhe in the scDNA structure. MYT2 is able to
change the writhe of the DNA, without altering linking num-
ber, upon binding to these regions. This hypothesis is consis-
tent with the saturable and quantized nature of the banding
pattern of scDNA when MYT2 is bound. The preference of
MYT2 for scDNA may be due to some special structural
features, such as single strand or cruciform structures induced
by DNA supercoiling [24,25]. Recent studies illustrate that
tumor suppressor protein, p53, binds to scDNA and generates
a protease sensitive ladder-like pattern similar to that ob-
tained using MYT2 [11]. It was suggested that p53 binding
to scDNA leads to local absorption of writhe and results in
DNA relaxation, an interpretation supported by electron mi-
croscopy [11].
Other DNA-binding proteins have been reported to bind to
scDNA and alter DNA topology. The most noticeable exam-
ples in eukaryotic cells probably are the non-histone chroma-
tin-associated proteins (HMG). Like MYT2, HMG1 and 2
preferentially bind to scDNA [26]. However, unlike MYT2,
detection of topological changes in the DNA required the
addition of exogenous topoisomerase I [10].
The high sequence identity of MYT2 with the pFR18 rep-
licase suggests that MYT2 might be involved in DNA repli-
cation. Indeed, microinjection experiments support this hy-
pothesis. Injection of MYT2 mRNA into NIH 3T3 cells
stimulated the G0 cells to enter S phase and synthesize
DNA in a dose-dependent manner. Microinjection is an es-
tablished method to introduce macromolecules into living
mammalian cells to study their mitogenic activity [27]. Several
oncoproteins, proteins involved in signal transduction, and a
number of cell cycle proteins have been shown to stimulate
DNA synthesis and to induce quiescent cells to enter S phase
using microinjection techniques. For example microinjection
of ras gene product p21 showed that this oncoprotein was
able to override the G0 block of growth-arrested mouse ¢bro-
blast cells, inducing the cells to enter S phase, and inducing a
temporary morphological transformation [16]. The microin-
jection of inositol phospholipid-speci¢c phospholipase into
NIH 3T3 cells produces similar e¡ects as do c-myc [28], src
[29], MAP kinase 1 [30], cyclin E [31], cyclin D1 [32], and G1
cyclin-dependent kinase C [33]. Since DNA topology plays an
important role in replication [1^3], it makes sense that MYT2
is able to alter DNA topology and stimulate DNA synthesis
in NIH 3T3 cells. It is interesting that p53, which also binds to
and relaxes scDNA, has an inhibitory e¡ect on the cell cycle
[34]. In summary, we suggest that MYT2 represents a novel
DNA binding protein that can stimulate DNA synthesis in
quiescent cells and may play a role in cell growth.
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